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Foreword
On October 16, 1978, Joshua Lederberg was installed as pres
ident of The Rockefeller University. A Nobel laureate and a
major contributor to modern genetics, Dr. Lederberg succeeded
Frederick Seitz, the distinguished physicist who served as pres
ident for 10 years and under whose leadership The Rockefeller
University Council was founded.
As part of the installation activities, the Council sponsored
a colloquium on the outlook for biomedical research and
education from the vantage points of the University and its
two nearest institutional neighbors-Memorial-Sloan Ketter
ing Cancer Center and Cornell University Medical College.
The three speakers not only provided unique insights based on
their individual involvement in the scientific pursuit, but also
voiced concerns shared by the institutions they represent. Some
of the major themes emerging from the colloquium were
explored, eloquently and trenchantly, by Dr. Lederberg in his
installation address.
We are indebted to the generosity of The Carl and Lily
Pforzheimer Foundation that makes it possible to present these
four statements to the wider audience they deserve.
JAMES A. LINEN III
Chairman, The Rockefeller University Council
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The Capitalism of Curiosity
GERALD M. EDELMAN
Vincent Astor Professor, The Rockefeller University

Perhaps I should begin by admitting that it is not my habit to attend
parties of the Jet Set. However, it was once my pleasant fate to attend
a soiree at which I met Andy Warhol, the artist. He told me, after
learning that I did scientific research, that he was very interested in
science. Indeed, he said that he received loads of scientific journals,
none of which he was able to understand. He found that regrettable
and then, after some chitchat, he said shyly, "Do you mind if I ask
you a question?" "Please, go ahead," I replied. He looked up pene
tratingly and said, "Why does science take so long?"
I tried to answer this question by drawing analogies to some of his
paintings of famous movie stars, but didn't get very far. What I tried
to explain was that a scientist cannot be satisfied only with a beautiful
image or idea, but must be able to make sure that the idea corresponds
to some state in the outside world-a rather more difficult enterprise
than simply imagining beautiful theories. Finally, I tried to discuss
some of the artistic beginnings of science, because I think that, in their
initial moments, art and science are very similar.
I'm afraid I didn't succeed very well in these explanations. I hope
to do somewhat better today by trying to express some thoughts on
both the psychology and the economics of basic research, using my
field-immunology-as an extended metaphor. In particular, I want
to draw your attention to an idea that lies at the center of immunology,
both because it has staggering implications in its own right and
because it offers fertile suggestions for the subject of my talk today.
My main purpose is to make two general observations. The first is
that basic research is necessarily an inefficient process. It is not subject
to ordinary rules of management and stewardship. Instead, it develops

rich and unpredictable stores of facts and ideas that comprise a kind
of research capital, which can be spent later for such practical ends as
the cure of disease. But, like all other capital, most of it can't be spent
before it is accumulated. Many people think that the line from
curiosity to application is a straight one; I do not agree. •The fact is
that research capitalism or the capitalism of curiosity follows a quirky
and difficult route, in no way subject to the ordinary rules of econom
ics.
My second observation is concerned with real capitalism as it bears
upon the funding of scientific research. There are certain features of
this funding that no sane capitalist would tolerate in his business. In
the latter part of this talk, I will explore that assertion, but for now let
me just state that there is an important link between the capitalism of
ideas and that of material resources. This link is most indirect,
however, and to make it effective requires a tolerant and wise view on
the part of both research administrators and the keepers of the public
funds.
Basic research is a reflection of a kind of play. This feature tends to
be obscured by the technical and planning aspects of research that
scientists must make one of their major concerns. Nonetheless, I believe
that the spirit of play underlies most basic research efforts. You can't
make play efficient without ruining it. If that is true, the imposing
question becomes: Why pay scientists to play? My reply is that there
is no other way to assure that proper climate in which fundamental
discoveries about our world can be made.
The task of basic research is to discover and describe significant new
features of the world under the guidance of a surmise, hypothesis, or
theory. This is frequently misunderstood. Often I've had graduate
students ask in the middle of an experiment, "Why are we doing this?
Can't we just go to the library and look it up?" That kind of question
from students of science might. seem astonishing, but it indicates a
point of view that is common even in specialized precincts. The answer
is, one can't look it up-one guesses and one tries. Very often there are
other misconceptions about the scientific method. Whatever it is, this
method is not a formula to calculate discoveries. It is something to
tidy up one's fumbling and guesses 'after one has finally found some
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apparently coordinated facts or clues. I shall discuss this a bit by using
immunology as an example, fo order to give you some sense of the
direction of discovery and research in a basic area with which I am
familiar.
Curiously enqugh, backboned animals must do something like this
guessing and tidying up in order to protect their individual integrity
by means of immunity-in other words, they must recognize foreign
molecules by use of their immune systems. Let me indulge in a
somewhat lengthy digression and consider how this is done. I think
such a digression may be illuminating, for some of the principles that
are exemplified by this biological system come close to those that must
guide basic research itself.
The problem in immunity is to distinguish self from non-self. To
put this in a more sophisticated fashion, the immune system must tell
the difference between the shape of foreign molecules and the shape
of molecules that belong to a particular individual. The way in which
the immune system does this is surprising. The system is distributed
throughout one's body in the bone marrow, in the thymus, which lies
.just behind the breastbone or sternum, in the spleen, which can be
found under the left rib cage, and in a variety of small organs called
lymph nodes, which are distributed all over the body. The immune
system develops during embryological development and early infancy
and consists of a rather large number of cells; in a man, perhaps that
number exceeds 100 billion. These cells, called lymphocytes, circulate
back and forth in the blood and percolate through a variety of organs
in the body. They move through various vessels; and finally they
police the entire body. The only exception is the brain, which is sealed
off by its surrounding bony structure, and must have other ways of
handling immune defense. From a narrow point of view, these lym
phocytes must deal with this problem of defense. But, as I said before,
from a more basic viewpoint, they make the distinction between self
and non-self, a fundamental process in more highly developed orga
nisms.
The problem, therefore, comes down to one that was first investi
gated in chemical detail by Karl Landsteiner, who worked in this
University in its early days as an Institute: How is it possible for an
Capitalism of Curiosity
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organism to tell the difference in the actual, three-dimensional shape
of one molecule as distinguished from another? The rough answer is
by means of a very special molecule called immunoglobulin, or
antibody. This molecule, which makes the key distinction between self
and non-self, resides on the surface of the lymphocyte. Ten-thousand
to a hundred-thousand antibody molecules stick out like little fence
posts on the lymphocyte surface. Within the lymphocyte is its nucleus,
containing the DNA with all the genetic instructions; on the periphery
of the cell is the plasma membrane, which contains the antibodies. It
is important to point out how small the immunoglobulin is compared
to the cell-the molecule is so small that it can't even be seen in detail
by the electron microscope.
In order to know how this molecule works, we must somehow see its
structural details. Now, the immunoglobulin molecule has an intrigu
ing structure with which I have been concerned for about twenty
years. It is made up of a large number of components, but, as I said
before, the molecule is still very small compared to the cell itself. A
few of its structural features are particularly important. First of all, it
is a T-shaped structure that is symmetrical; the stem of the T sits on
the cell. At the end of both arms of the T is a cavity known as the
antigen-combining site; this is the place at which the molecule recog
nizes a foreign shape. To see what this recognition might be, imagine
a cookie and a cookie-cutter, if you will, each complementing the
other; the invading molecule (the cookie)-or the antigen, as it is
called-enters and is bound closely in each of the two cavities (the
cookie cutters) of the immunoglobulin molecule. That means that
these cavities must have a specific shape. In order to recognize different
foreign molecules, the cavities on antibody molecules affixed on dif
ferent lymphocytes must have different shapes. Perhaps I should
change the metaphor-instead of cookies and of cookie cutters, it
might be better to imagine thes� cavities to be a large number of locks
into which fit a large variety of unknown keys, which are the foreign
molecules.
When the antibody molecules bind foreign molecules, a great
number of reactions take place: more cells are made, and a variety of
mechanisms are called into play to destroy or break down the foreign
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molecules or otherwise entrap_ them. Obviously, this is a major mech
anism for the body's defense against disease. In bacterial or viral
invasions, for example, the bacteria or viruses are in some measure
destroyed or inactivated as a result of this binding process.
My main concern in trying to do research on immunity has been
the question: How does this sytem of locks and keys work? This
question is not easy to answer because of the number of "locks" and
"keys" one has to deal with. I think you would be startled if I told you
that, above a certain size, there is hardly any molecule of defined
shape that the immune system cannot respond to, including molecules
that have never before existed in the history of the human species or
any other species. This statement is a close approximation to the truth,
with some allowance for the special manipulations that have to take
place within the immune system.
Now, common sense would tell you that, in order to accomplish
such a feat, the immune system has to know something about the
shape of the key before it puts the shape of the lock into place. This
idea, which is called "instruction" in the field of immunology, has
turned out to be false and inadequate. During the development of the
system, no information whatsoever exists on the shape of a future
invader that is going to be recognized by this system. Astonishingly,
the system contains all of the necessary potential information before
it ever "sees" anything out in the world. This is so because it is a
"selective" system. It does not receive instructions in the way dough
does when a cookie cutter cuts out a cookie or in the way a master key
is made by impression from a lock. In fact, the system has so many
different kinds of locks that virtually any key will fit more or less well
into one or more than one of them.
Each of the lymphocytes that I've talked about has its own antibody
molecules sticking out with their distinctively shaped locks, or cavities,
waiting for a foreign molecule, the key. When that foreign molecule
comes along-for example, in the form of a virus of a particular
shape-it will move along among this collection of cells, and find
those that bind it more or less well. When the virus does bind, an
amazing mechanism goes into play that says, "Make more of that kind
of lock-that is, make more of those kinds of cells and make more of
Capitalism of Curiosity
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those kinds of antibody molecules with that particular shape of "lock."
According to the experience the animal has had with a variety of
foreign molecules, or keys, this command increases the proportion in
the system of the kinds of locks that happen to fit these keys. This
principle of selection accounts for responses to transplanted skin, to
transplanted hearts, to allergies, to typhoid or polio immunizations,
and so on. The principle is known as clonal selection; clonal, because
the stimulated cell actually divides to form a clone, or asexual progeny,
of a single cell.
This is an astonishing principle. It is obvious that, at a particular
time, each immune system could not actually have a sufficient number
of locks to recognize everything in the world. What it does have is a
very large number of different ways of arranging to build the lock
portion of different antibody molecules to achieve different shapes.
The calculated number of potential locks, or antibodies, that can be
made by such a rearrangement is unbelievably enormous. That process
is activated very early in each individual's life. When something
foreign comes along, it encounters many locks as it circulates, and a
reasonable likelihood exists that it will find one that it fits more or less
well.
The surprising feature of this system, which is, in effect, a system of
discovery, is that it appears to be highly efficient. But fundamentally
efficiency cannot be the issue, for the system must deal with an unknown
future, one in which the animal cannot tell what foreign material it is
going to encounter. And the world is very rich in foreign materials!
Therefore, the immune system is apparently a wasteful system at the
level of the repertoire of locks that exists in the animal-some will
never be used at all. But once a lock is encountered, the system is
extraordinarily effective in amplifying that encounter and developing
the right kind of antibody.. Perhaps it might be called a learning
system, in which the body learr�s how to deal with this world full of
foreign molecules as a result of the very effective way in which the
selected cells divide and make more kinds of antibodies. The attempt
to understand this intriguing process has formed the saga of immu
nology during the last fifteen or twenty years.
By now we pretty much understand the molecular principles upon
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which the extraordinary idea of clonal selection stands. Dr. Lederberg
once published an article on what he called at that time "instruction
and election" (not instruction and selection), and this article was one
of the fundamental contributions to the idea that there is a pre
existing diversity of antibodies. This concept has had deep implications
for biology. But the story I have told also has a deep implication for
psychology of research. Because of the unpredictable nature of the
future and the complex structure of the world, we need in scientific
ideas and observations the equivalent of a repertoire of different pre
existing antibodies. Of course, this does not imply that we must not
plan, use logic, and instruct ourselves as much as possible. But I
believe that, if you study a scientific problem long enough, you come
to the conclusion that you will be faced with an irreducible minimum
of facts and ideas, which, when first conceived, seem to have little
practical meaning. They seem as gratuitous, if you will, as some of
these antigen-binding cells with their antibodies. Mind you, the cost
of having such a system of antibodies is that most of the cells don't do
anything at all. They simply sit there, live, wait, and die. But this
"cost" of diversity is the price the organism must pay to get the cells
that are efficient in their response. The fact that we are all alive in this
room indicates just how good such a system can be.
In research, we often don't know the connection between the results
of our studies and their practical applications. There is one reassuring
historical point, one made by Lewis Thomas and a variety of other
knowledgeable and wise people: almost always, apparently inefficient
basic research pays off handsomely, efficiently, and in unpredictable
ways. It is obvious that a new vaccine which prevents a major
incapacitating illness is a vital development in both humane and
economic terms. What is not obvious are the humane and economic
benefits of a basic discovery that organizes a field, opens new vistas, or
makes development of a vaccine possible. What is the dollar-and-cents
value of the structure of DNA or, for that matter, the founding of
biochemical genetics, a milestone that Dr. Lederberg helped to mark?
To take a more personal example, I am always embarrassed when
reporters ask me to explain the practical benefits of my own work on
immunoglobulin or antibody structure. That work has cured no
Capitalism of Curiosity
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disease, but I do think it has helped to reorganize our thinking about
all diseases related to the immune process and it also allows us to
envision new diagnostic and therapeutic tools. For example, now that
we know its structure, the antibody molecule can be cut up in various
ways and its properties altered in order to treat people more efficiently,
in ways that the body itself has not yet managed to contrive through
out evolution. In other words, this kind of knowledge is basic research
capital, which is ready to be invested in useful and humane projects.
I must reemphasize that, for the most part, the accumulation of this
research capital was not in a straight line or for a predicted end result.
Having digressed so far to make the point that there is a necessary
inefficiency in accumulating research capital, I now turn to my second
assertion, which is related to real capitalism and the support of
research. At the outset, I want to emphasize that I have enormous
admiration for what has taken place in this country since World War
II in founding and developing various institutions, such as the National
Institutes of Health and the National Science Foundation. In partic
ular, I want to praise the whole system of peer-group review, which
calls upon scientists to review the merits of other scientists' proposals.
Nevertheless, it seems to me that there are two areas in which this
system may be in need of larger insights. These are, first, the failure to
recognize sufficiently that a fairly large amount of basic research
capital is necessary before application is possible. In the absence of
this capital, direct mission-oriented pushes or large task-forces almost
always fail. Second, to make a more practical point adumbrated in
my earlier remarks, research support strikes me as a curious form of
capitalism indeed-one which lacks the usual buffers of space, time,
or money that a capitalist or a businessman would employ to put his
funds to the best use. Basic research funds usually are given via grants
after proposals have been reviewed by scientific peers and agency
officials, and after the funds ha�e been appropriated by the Congress.
The funds usually are given according to strict budgets for defined
periods of time, and this is all well and good. But a close scrutiny of
the process indicates that if there are any untoward developments in
a project, or if needs change during the research period, the scientist
has recourse to only one method-he must reapply over time periods
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that usually are too long to do him any good or to meet the immediate
crisis that he faces. And, at the other end, even if an official at the
NIH, for example, has understood what the problem is, he has a very
hard time rustling up contingency funds to tide the researcher over.
The needs for 4ccountability and the political process in some sense
act in conflict with the needs of the researcher.
There are related needs, which are particularly striking these days.
One of them is the increasing cost of setting up young researchers in
a new research venture-beginning assistant professors, for example.
Everybody in our kind of enterprise knows that these young brains are
the ones that we can count on for new developments and new
imagination. Furthermore, it no longer is possible to have every kind
of field represented in every good institution. There must be some
fractionation of fields; this principle has been adopted at The Rocke
feller University with great success. The question I must ask is, "Given
all of these needs, would a businessman run his company without
some form of buffering provided by equity, investment capital, and
bank loans?" I think it unlikely, and would therefore suggest that
perhaps the time has come to consider the idea of a research bank, a
place in which government funds are placed to buffer the various
situations and contingencies that arise during a research project. Such
a bank could serve to meet a number of contingencies that confront
the researcher in the course of his basic research. Let me illustrate this
a bit by discussing research budgets for a moment.
A typical budget proposal, taken from my own laboratory, demon
strates the definite kind of funding system that requires a specific
budget. The budget must account for the time and effort of the various
people concerned with a particular project, and include some guesses
about the kinds of scientific equipment that are necessary. A fairly
healthy part of the budget is dedicated to research animals and general
laboratory supplies, as well as to some costs for contracts, publications,
and shop expenses. But my main point is that this budget, which in
year one started at $67,000 or so for salaries, grew to $78,000 as a
result of inflation and other unforeseen contingencies, so that the total
proportion of the budget dedicated to salaries has become huge. These
days, the remaining unencumbered funds available to a researcher for
Capitalism of Curiosity
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a reasonably modest project, such as this one, is a very small percentage
of the total. Furthermore, a laboratory like mine must make multiple
requests of this kind to different agencies. If anything happens to
endanger some of these funds-$11,000 out of a total of $96,000, for
instance-the project is in jeopardy. The salaries are paid and increase
with the years, but the project cannot go ahead. Here is a typical
situation in which a rapid mechanism of buffering of funds insured by
a loan from a research bank could be of very great use.
Another area pertinent to this suggestion relates to grant renewal
and delays in the grant decision-making process. If I have three or
four grants supported by different agencies with different starting and
ending periods, a really remarkable juggling act is essential, if a grant
ends, to keep a constant flow of money coming to the laboratory. It
requires the cooperation of officials in the various agencies, as well as
the cooperation of officials in the University. Although a grant is
awarded in principle, a grant-decision delay means that the money
simply is not there, and some way of buffering that money must be
provided. Moreover, as I mentioned earlier, one of the chief challenges
to a researcher working in this and other universities is to set up
enterprising and brilliant young people in their new laboratories.
Unfortunately, because of budget stringencies and delays, this mech
anism has not been worked out completely within the usual grant
frameworks. Finally, I think there is some merit in considering the
establishment of a central clearing house for valuable scientific equip
ment, which is becoming more and more expensive. A research bank
might have some function in such a plan.
Of course, as it stands, this proposal of a research bank is very
general, and I am aware that there is a conceptual problem: basic
research provides no direct profit and no obvious tangible product.
But, as I have tried to show, science has an invisible product with
enormous implications for our_ economy. Indeed, some economists
have estimated that over 30 percent of the economic development in
this country since World War II can be related in a more or less direct
way to the basic research accomplished in that period. Moreover, I
am told by people such as Gus Kinzel, former director of research for
Union Carbide, that basic research is much less costly than applied or
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developmental research. For e�ery dollar dedicated to basic research,
he tells me, about $10 must be spent on applied research, about $100
on development, and $1,000 on plant. Basic research, essential basic
research, is cheap, given the return.
I know how much work would have to go into thinking through the
practical details of a research bank. This is not the place for these
matters, and the idea may not be practical in the end because of the
political difficulties. All the more reason for institutions like The
Rockefeller University, the President's Office of which already serves
many of the functions of a research bank, as I suspect Dr. Lederberg
has already found out. Indeed, it has always been a local tradition
here to provide some of the buffers that I have been talking about, but
it is a hard tradition to maintain in the face of mounting costs. Clearly,
we must continue to receive support from enlightened private sources,
for that support has been one of the key reasons this place has
remained excellent. I join with the others here in the justifiably
optimistic hope that Dr. Lederberg will deepen and adorn the great
tradition of the capitalism of curiosity at The Rockefeller University,
a tradition composed of both private and public support, of indepen
dent laboratories, of magnificent ancillary services, and of a fervent
belief in the intellectual excellence of the workers, tempered by an
understanding of how that excellence is achieved. That understanding
stands upon the principle that basic research does not run in a direct
line from curiosity to achievement and use.
So, as I said to Mr. Warhol, perhaps too lugubriously and with a
personal poignancy I needn't discuss, "Science does take a long time
to do well." Given that, researchers must have the freedom and the
time to pursue their ideas. In an atmosphere of mounting frenzy and
push programs, which-at least in the public sector-seem to be more
and more prevalent, perhaps it would be well to remember that ideas
do not come every day. Certainly good ideas don't come every day. I
cannot help paraphrasing in a somewhat inexact but essentially correct
way the story about Paul Valery, the French poet, who went to visit
Einstein because he was interested in poetic creativity and scientific
creativity. He asked, "What do you do every day?" Einstein said,
"Well, I get up and shave and I take a walk and I think, and by that
Capitalism of Curiosity
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time it's lunch and then I'm a little tired, and I think a little more in
the afternoon, but by that time I'm really tired, and I have supper
and I go to bed. Perhaps I have a sail or another walk, but that's
about it." Valery said, "Do you keep a notebook?" Einstein looked at
him, startled. "What on earth for?" he said. "You know, to write down
your good ideas." Einstein said (and I believe this is a true story),
"Look, I don't get many. And don't worry, when I get one, I don't
forget it."
Once having assured the quality of a research climate, I believe that
the best policy is to leave the researchers alone to their play. That is,
do not get in their way, for an excess of zeal leads only to logic rather
than to imagination. I would like to end with one comment and one
further anecdote. The comment is by William Butler Yeats, who was
a great poet but, unfortunately, a great enemy of science. Nonetheless,
he obviously understood imagination and creativity. He said that bad
art is will substituting for the imagination. This is also true of science.
Bad science, fundamentally, is will substituting for the imagination.
The anecdote is told by Freud. During the Napoleonic Wars, an
emergency was anticipated and Napoleon called his councils of war
and consulted his generals about what should be done. An old general
said, "The most urgent thing to do is wait." To my mind, this a good
description of the psychological tone of doing basic research. It is
dominated by the urgency of waiting. No highly structured or pro
grammatic approach will succeed as well as that form of urgency. In
places like The Rockefeller University, with the love that its scientists
haye for their discipline and their art and their science, we have
nothing to fear about the absence of urgency.
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Medical Education and Biomedical Research
THEODORE COOPER
Dean, Cornell University Medical College

This is a happy occasion for all of us-for different reasons. We at
Cornell are excited and expectant. We congratulate The Rockefeller
University; we congratulate President Lederberg; and we even con
gratulate ourselves. Indeed, we are fortunate to be your close neigh
bors, your colleagues, and, we hope, your partners in many future
scientific and educational endeavors.
Among the many challenges and opportunities that you will con
sider, some are specific to the York Avenue institutions. Among the
greatest of these is the achievement of the promise raised by the
proximity of three great institutions with some common heritage, some
common purpose, some common programs, some common problems,
some common needs, and many uncommon people and ideas. This
commonality-an old dream that I have heard ascribed to many of
you here today-should take real form now, because in our own ways
we all need it; New York needs it; the American systems of biomedical
research and education need it, not for survival, but to be able to
prepare for the future.
It is not difficult to convert happy occasions such as this into gloomy
ones simply by reporting most of the discussions being held by national
leaders in medical education and research. The commentary can only
be characterized as ambivalent, guilt-ridden pessimism. We are being
convinced that we are guilty of fraud, financial irresponsibility, and
failure. Indeed, for a system that has done so much good, it is
remarkable how it can be perceived as so bad. The explanation of this
perplexing and frustrating situation lies in the changing criteria of
social justification and evaluation.
We in this country have accepted as appropriate and right that the

government should support medical research and medical education.
We have· gone further. We have said that, in the public interest, the
government should support a very large portion of the costs of medical
research and education, and we have attempted to develop a system
of public and private institutions that could react to these assumptions
as if the institutions-public and private-operate the same way.
The character of medical education has been greatly influenced by
research activities in our institutions, even to the extent that faculties
have been refashioned and facilities redesigned. The remarkable im
pact of research can be seen on medical practice. And as medical
practice changes, so does the educational process. Thus, research has
had both direct and indirect influence on medical education. Financ
ing has been a factor; the character of the faculty has been a factor.
No longer is the philosophy dominated by "the practitioner." The
students are selected by people with different viewpoints. The empha
sis, the orientation, has changed. Medical education presents other
unique reflections of the realities of financing. Large and growing
amounts of money from practice are underwriting faculty salaries. As
federal research funding is increasingly unable to meet the cost
patterns that were set ten years ago, practice plans are being looked
into in order to bridge the gap between commitments and institutional
resources. Faculties are rationalizing these changes by agreeing that
perhaps such plans could come close to income parity with the private
practitioner.
At the moment, no greater force challenges our philosophies of
operation than cost escalation in medical care. So pervasive is this
concern that no sector-education and research included-is free from
suspicion of "fat," excesses, waste, greed, and irresponsibility. So loudly
and often have the charges been made that the allegation is now the
conclusion. As a consequence, we are accepting refinancing without
changing aspiration or expectat�on. We are not even willing to suggest
that perhaps it is not possible to do all things with less money. We are
reluctant to challenge government-mouthed righteousness, because we
do not wish to offend those who administer our monies. This is a well
recognized consequence of dependence-the loss of flexibility that
accompanies the "emperor's new clothes" syndrome.
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Social justification is being interdigitated with scientific evaluation
in an interesting but dangerous way. It is one thing for society to
decide "it isn't worth it," but quite another to conclude that not being
worth it means that it has no intrinsic merit or, worse, that it was
undertaken with malicious deceit in mind. In order to attempt to meet
every possible objection, every human failing, the government is
attempting to direct the system, to achieve social objectives, and to
guard against abuses by creating more and more specific restrictive
legislation and regulations. In a very real way, the proliferation of
rules and reporting systems is a greater problem than are the deficits
of funding for our institutions.
As one reviews the forthcoming legislative calendar, no matter what
item is encountered, one is faced with recidivism in various ways:
1) The Health Professions Education Bill will lead to requests for
more federal direction of who can go to medical school and what
should be taught. At the same time, there will be withdrawal of
funding and increase in control. The student loan provisions and
regulations are already incredible. For a loan of $30 + thousand, the
student is expected to pay $140 + thousand.
2) The Research Authorization Bills will attempt to change empha
sis, will increase reporting, and will decrease promises of future sup
port. The administration's new "plan" will not have significant impact
for the next two years and, if it did, it would be to "cap" the system
in the name of stability.
3) The Health Planning Legislation will intensify the regulatory
activities of local bodies. Medical colleges will be increasingly involved
and ensnarled. As dependence on clinical-practice income increases,
our vulnerability to political manipulation increases.
4) Measures to change practice through financing will receive the
greatest attention. Reimbursement for teaching hospitals will be
changed in efforts to reduce costs. Limits on incomes will be proposed.
Limits on services also will be proposed, while at the same time more
and better care for everyone through National Health Insurance will
be promised.
5) The Drug Reform Act and some recent regulations relating to
clinical investigation in academic centers, proposed by the Food and
Medical Education and Research
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Drug Administration, will magnify reporting, recording, and review
ing, way out of proportion to any benefit they could possibly obtain.
6) The Federal Trade Commission will pursue the health professions
with the doctrine of salvation through competition.
The list is long and, if looked at in isolation, presents a• depressing
picture. But federal brushes should not be painting the whole canvas.
There are several encouraging signs. The most important of these is
the revival of intellectual independence in our private institutions.
The evidence is substantial: the refusal of capitation funds by several
institutions rather than acceptance of federally dictated admission
policy; the successful campaign against restrictive DNA legislation;
the successful campaign against implementation of Sec. 227 of the
Medicare Law; and a meaningful modification of the Office of Man
agement and Budget circular A-21 on overhead determination.
The biomedical researchers, the medical colleges, and the health
science centers are less reluctant to work openly with business, partic
ularly with the industrial world. Part of the reason behind this
conversion is financial self-interest. Yet it is a very important evolution.
The admirers of the American system of enterprise can come out of
the closet. The association with government is no longer free of
implications of control and direction. And, in fact, there is growing
concern that the directions a required and the controls imposed by
government are less and less justified on appropriate social grounds,
not to mention scientific and academic critera. We would be well
advised to restore independence through balanced pluralistic interac
tion. We should be making scientists, physicians, and other health
professionals aware of the career potential in nonacademic and non
governmental settings.
One can even make the remarkable observation that the academic
and practicing wings of the medical profession have come closer
together. "Organized medicine" �as helped the academic brotherhood
in meaningful ways in Washington by lobbying for legislation that is
helpful to medical schools and the scientific community, including
appropriations for the National Institutes of Health and sound posi
tions for education legislation in the health professions. These have
put a different perspective on the "town-gown" situation as we move
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into the need for rapid integration of_ new knowledge into clinical
practice through education. The busy practitioner knows he has a
reliable friend and critic in the academic scientist-physician who can
help sort out the meaning and quality of newly proposed methods of
diagnosis and treatment.·
Yes, not all the signs are negative. The list of positive trends, like
the apparent success of the voluntary cost-containing efforts, is grow
ing. But the most important reason for optimism lies in realizing how
much we are going to be able to do for people in the future. Social
and scientific forces will insure high interest, growing expectation, and
need for innovation, experimentation, and education. Too many
people have viewed modern medical technology as approaching the
ceiling of possible intervention on disease treatment and prevention.
Dr. Lewis Thomas has repeatedly warned of this short-sightedness. If
one looks ten years down the road, the possibilities are staggering.
From immunology, genetics, neurosciences, behavioral science; from
pharmacology; from bioengineering will come great insights and tools
for the practice of general medicine, not superspecialty medicine.
The "new-old" panacea for our social-medical ills, i.e., preventive
medicine, will take on new meaning because we shall have real tools
to find the susceptible, to make predictions far beyond statistical
correlations alone. We shall be able to interpret biological response to
social ills with confidence.
At our medical college, we have begun the process of preparation
for tomorrow. We have recognized that we can no longer do business
in the same old, comfortable way. We accept that there are limitations
to our resources, but not to our vision. To avoid becoming a part of a
seedy, aristocratic home of solid mediocrity, we shall seek to improve
our productivity. We shall regain independence of action through
reduced dependence on government. Cornell Medical College spends
about one-third of its resources on research, one-third on education,
and one-third on services. We shall repartition our "hard monies" in
favor of the support of education and science. We shall redesign our
clinical programs with The New York Hospital and our other affiliates
to provide more service to the community at less cost per citizen. The
future of clinical teaching will demand diversjfication, a broader
Medical Education and Research
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variety of clinical experience. The aggregate expenditures for clinical
service and education will increase, but will derive from various
sources. The national refinancing of health services implied in what is
called National Health Insurance will offer both opportunities and
problems. The problems are conceptually manageable, at1d we need
to get on with preparing how to accommodate them.
Our independence-our productivity and our ability to dream
will come through.strong associations with The Rockefeller University
and Memorial Sloan-Kettering Cancer Center. Therefore, we wish
you success, for we cannot help but grow with you.
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The Competing Roles of Basic and
A pp lied Research on Cancer
LEWIS THOMAS
President, Memorial Sloan-Kettering Cancer Center

It is a privilege to be here today, on this great occasion in the life of
The Rockefeller University, and a quite special and personal pleasure
for me as an alumnus of the venerable Rockefeller Institute, as a
trustee, and as a representative of Memorial Sloan-Kettering. My
remarks this morning are made in this latter capacity. I want to
explain some things about what my institution is up to, just across the
street. It is not widely known that Memorial Hospital was placed
where it now stands, 40-some years ago, because John D. Rockefeller,
Jr. was convinced that cancer research and patient care were going to
need this proximity to both The Rockefeller University and Cornell.
First off, I'd like to say something candid, ambitious, and self
interested about the future of Memorial Sloan-Kettering. Obviously,
we have a single, very long-range mission as our assignment from
society: to do whatever becomes possible to do in order to reduce the
threat of cancer, and, in the best of worlds, to get rid of it. This mission
is self-evident from our title and charter, and the ambition to get this
accomplished is what drives the place along. However, there is another
mission and ambition in the back of the minds of many of us. It is to
form intellectual linkages as close as possible with both our distin
guished neighbors, the Rockefeller and Cornell, so that all of us can
capitalize on the lucky creation, here on York Avenue, of as concen
trated an aggregation of scientific firepower as exists on a single city
corner anywhere in the country.
I am convinced that there are new symbiotic arrangements that can
be worked out among these three institutions that could have the
effect of greatly enhancing the kind of science done here, particularly

in such times of inadequate funding for biomedical science as surely
lie ahead for all of us in the next decade or more. Moreover, I am
convinced that closer ties among us, if worked out carefully and with
taste-which means, in my view, with a good deal of informality and
looseness, and worked out by the faculties concerned-would have the
net effect of making it enormous fun to work here, especially for those
generations of the brightest young people, in training for careers in
science, whom we all hope to see agitating back and forth across 68th
Street and across York Avenue. It goes without saying that the quality,
braininess, and enthusiasm of the very youngest people, those just
beginning their scientific careers, provide the most certain and exact
ing test of success for institutions like these three, whatever the
differences in our structure and mission.
And, of course, there are great differences, needing understanding
and frequently needing explanation. Across the street, Memorial
Sloan-Kettering is a single-mission institution, dedicated to the con
quest of a single disease. This suggests to some observers, at a distance,
that our science must be highly targeted, programmed in every detail,
and squarely in the area of what is called applied science. It is
abundantly not so. On the contrary, virtually all of the research in the
Sloan-Kettering Institute, amounting to about $30 million per year,
would have to be classed as basic research, if this term is taken to
mean, as I mean it, the exploration of tentative hypotheses in an
atmosphere of high uncertainty. It is this matter of uncertainty that
defines basic research, in my opinion, and differentiates it from applied
science. All of us can make guesses about the underlying mechanisms
which are responsible for switching a normal cell into the mode of a
neoplastic cell, but none of these guesses can be regarded as anything
like a sure thing. The research has to be based squarely on making
guesses, and for a biological problem as broad and profound as cancer
it is necessary to cast a very wide net, and to make up stories,
hypotheses for testing, in many different fields of biology. The labo
ratories of Sloan-Kettering are engaged in this kind of enterprise,
covering as v.ride a cut as is logistically feasible of the fields that seem,
at a guess, to be somehow or other relevant to the underlying process
of neoplasia.
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Research of this kind cannot really be targeted, nor can it even be
centrally controlled or run by committees within an institution; it
requires the imagination and mind-changing of individual investiga
tors. For instance, there are some pretty good reasons for supposing
that immunologic mechanisms may be involved in natural defense
against cancer, and it can be imagined that most of us do not develop
cancer because of the proper functioning of such mechanisms, but in
order to study this matter it is necessary to learn a great many things
about immunology itself, in general; the time has not yet arrived for
the launching of any kind of applied targeted research program for
immunology in cancer; there is nothing resembling certainty here; it
is plainly a matter needing basic science of the most uncommitted,
undifferentiated kind. The same thing must be said for our programs
in virology, in molecular genetics, in cell differentiation, in aging, and
all the rest. None of us can predict, with any sort of assurance, whether
or when any one of the lines of research will turn out to be actually
connected with the cancer problem, in the sense of being useful or
usable. It is something like gambling, but there is, in real life, no other
way to go about it.
Meanwhile, there is a certain amount of applied research that can
be done, and must be done. Despite the plain fact that we are nowhere
near to the center of things in the problem of cancer, there are some
extremely useful measures that can be taken to treat the disease, and
these must be tested, tried out, and improved upon if possible. This
kind of research consumes the energies and time of a large group of
clinical investigators in Memorial Hospital; most of these people hold
simultaneous appointments in the Sloan-Kettering Institute and work
side by side with their colleagues in the basic research laboratories.
Therapeutic research is the hardest and most demanding of scientific
endeavors. It has to be done in a totally different mode from basic
research. In the first place, it can only be done well when highly
centralized, carefully programmed protocols are laid out in their most
intricate details, way in advance; committees are essential for both the
planning and the operation. You cannot go around changing your
mind whenever your mind feels like changing, which is the greatest
difference from what goes on in basic research (which, as I've said,
Basic and Applied Cancer Research
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works by mind-changing). Once a protocol is laid out and agreed upon,

everyone involved is expected to follow that protocol with precision
until the results come in. Biostatisticians stand as indispensable arbi
ters, before, during, and after the work.
We do not have a long history of first-rate applied science in
medicine, primarily because it is only quite recently that we've had
much in the way of genuinely basic information to apply. The best of
our achievements thus far have been in the field of infection, and there
may be a useful analogy here for the understanding of where we are
heading in cancer research.
I was a medical student in the mid-1930s, when tuberculosis was
the disease of most concern. Anyone, from infants to the aged, was at
risk. If you were lucky, you survived. If the diagnosis was made early
enough, and you were admitted to one of the many ·state hospitals or
private sanitaria devoted exclusively to TB patients, your chances of
survival increased. Rest was the only treatment-both for the body
and for the lung itself-by inducing its temporary or complete collapse.
No drugs helped.
It was also 1 ucky if the disease did not spread. If the bacilli reached
the central nervous system, that was the end. The doctor's main
function in tuberculosis meningitis was to make the end peaceful for
the patient and to comfort the survivors.
From the 1890s, when Koch discovered the tuberculosis bacillus,
basic research on the disease expanded worldwide well into the 1930s.
Gradually, investigators began to understand how tuberculosis spread
through communities, and early detection and isolation methods were
developed. The still-mysterious mechanisms that enable the tubercle
bacillus to destroy living tissue were explored, and environmental
factors were identified: crowding, malnutrition, genetic predisposition,
immune responsiveness, perhaps even the stress of living.
But throughout forty years, the single, crucial discovery was that
the tubercle bacillus was the sole cause of the disease. Other factors,
environmental or genetic, might contribute, but at the center, indis
putably, lay the bacillus. If it could be killed and the patient live,
tuberculosis could be cured. This achievement led ultimately to the
work of Selman Waksman, who, like Rene Dubos, explored the hunch
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that certain soil microorganisms might produce chemicals that could
curb the growth of competing bacteria.
But streptomycin was not good enough; it cured only those patients
in beginning stages of the disease. It could not reverse consistently the
devastations of miliary TB or TB meningitis. Also, it produced disor
ders in hearing and sense of balance if used over long periods or in
large doses. Nevertheless, streptomycin proved that the tubercle bacil
lus was vulnerable in living tissues and, subsequently, research led to
para-aminosalicylic acid and then to isoniazid. Tuberculosis became,
at last, a curable disease.
We do not yet possess information about cancer with anything like
the central significance of the tubercle bacillus in tuberculosis. Of
course, today we have clues that were unknown twenty-five years ago.
We know for sure that cigarettes are the main cause of lung cancer.
We are certain that other environmental pollutants, notably asbestos,
are implicated in various forms of the disease, and new agents, from
hair dyes to food additives, come under suspicion with remarkable
frequency.
But the identification of environmental carcinogens will not by itself
solve the problem, when they are as ubiquitous in nature as now
appears to be the case. We need to know the nature of the mechanism
in the cell which triggers its transformation from normal to neoplastic
activity. It has been suggested that a virus or some other infectious
agent is involved, although the idea seems less plausible now than it
did a few years ago. The switching mechanism remains a mystery,
and it is this problem that constitutes the major preoccupation of basic
science in cancer research today.
However, there is progress in cancer therapy despite the lack of
fundamental information about the process. Twenty-five years ago,
very little could be done in the way of specific or selective therapy,
and nothing could be done to prevent or restrain the metastatic spread
of cancer to other parts of the body.
Then treatment with chemicals became part of the arsenal. The
earliest chemotherapy was the use of nitrogen mustard, which is
related to the mustard gas of World War I. Some cases of leukemia
responded remarkably well, but the side-effects of the treatment were
Basic and Applied Cancer Research
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alarming and sometimes lethal. Modifications of the drug were intro
duced, then totally novel compounds, all with the capability of
interfering with the functions of rapidly dividing cells, and it became
clear that certain varieties of cancer were highly vulnerable to these
chemicals.
Even ten years ago, leukemia could be arrested in 50 percent of the
children affected, and other forms of cancer regressed as a result of
chemotherapy, even if only for short periods. The past five years have
produced more dramatic results. Hodgkin's disease is now curable
when treated in its earliest stage. Combinations of less toxic drugs, or
drugs plus radiation therapy, have given reason for hope-as in bone
sarcomas of children-that we can talk tentatively of cures. The
treatment of testicular cancer by use of platinum salts has recently
been spectacularly successful.
Obviously, not all forms of cancer respond equally well. We have
not found the right drugs; we have not found the right combination
of treatments. Most importantly, that triggering mechanism still eludes
us. But discoveries are coming faster and faster.
How did we get to this point? Do the improvements in our tech
nology for treating cancer thus far represent a feat of appled science,
or were they based upon basic science? It was, and is, a mixture of
both kinds of enterprises. At the outset, it was entirely empirical, and
for some years after nitrogen mustard, most of the effort consisted of
screening great numbers of compounds for anticancer activity, more
or less blindly. In recent years, however, it has become a considerably
more sophisticated undertaking, with molecular design now made
possible by today's more basic understanding of the kinetics of cell
division; it is now feasible to synthesize new drugs that are aimed at
interrupting one stage or another in the cell cycle, and both the
potency and the reduction of toxicity are problems that are open to
research by groups of chemists and basic pharmacologists such as those
now working in the Sloan-Kettering Institute, together with the
clinical scientists in Memorial Hospital.
The limitation of this line of research is well recognized by everyone
concerned. It is not really a specific anticancer therapy at all, any
more than radiation, even the extremely precise and effective forms of
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radiotherapy now used for H?dgkin's disease, is specific anticancer
therapy. The technology is aimed at rapidly dividing cells, and we
will be held at this level until we have learned more about the special
attributes and points of vulnerability of cancer cells themselves. It is
the best we can do at the present time, and it is certainly not the final
answer. But it does work, nonetheless, in some patients with some
forms of cancer, and it is still open to further improvement by research.
This kind of research can only be done by close collaboration between
basic and applied scientists, and it cannot be done at all without the
resources of clinical institutions like Memorial Hospital.
One very bright piece of news has come from all the work in
chemotherapy to date, and is often overlooked by the public, by critics
of the National Cancer Program, and especially by those critics who
believe (as I do not) that cancer can be reduced to a minor health
problem by changing the environment to prevent it; you could, I
agree, accomplish a great deal by eliminating cigarettes, and the
identification and elimination of industrial carcinogens is clearly a
worthwhile activity to which all of us ought to be committed. But it
is highly unlikely, I think, that we will ever find them all and, even if
we could, it is still more unlikely that we can change the way our lives
are lived drastically enough to get rid of them all. We simply do not
know enough yet to talk about preventing most forms of cancer, even
though this is the most laudable of objectives for applied science in
the long-term future. And even when we do know all there is to know
about the environmental causes, we are still going to have to face
cancer as a formidable health problem, and we are going to have to
treat it.
The bright piece of news is that cancer is, really, slowly, gradually,
becoming a treatable disease. I do not say this out of any institutional
self-satisfaction, nor with anything but discontent with today's forms
of treatment; they are not good enough, they do not cure enough
patients, and they are not directed at any central, causative mechanism
of the disease. Nevertheless, from time to time, much more often today
than just five years ago, they do work, spectacularly well, and this
means.something quite tremendous, to me, anyway. Even twenty-five
years ago, I would have said that such a thing would be forever
Basic and Applied Cancer Research
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impossible. I believed that cancer was simply a fact of life, a part of
the human condition, like mortality, a sort of tax on living in com
plexity. But today, to observe the rapid vanishing of huge growths in
the lung almost overnight, the shrinking almost to nothing of great
masses of malignant cells in the brain, is an absolutely extraordinary
thing to see, despite the knowledge that some of the cells are still alive
in there and will grow back again, sooner or later. We need a new
technology, perhaps an array of new technologies, to assure the
elimination of those last, still invulnerable, cells, but I have no doubt
at all that this can be done. It will not happen easily or quickly, and
we have a vast amount of basic science still ahead to do. Then there
will have to be other vast efforts in applied science, but I see no reason
at all to be skeptical on this issue. Cancer is no longer the blank
mystery it seemed, not very long ago. It has become an approachable,
ultimately solvable biological problem.
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INTRODUCTION OF PRESIDENT LEDERBERG
PATRICK E. HAGGERTY
Chairman of the Board of Trustees, The Rockefeller University

In three-quarters of a century, The Rockefeller University has had but
four leaders-Simon Flexner, Herbert Gasser, Detlev Bronk, and Fred
Seitz-and it has been fortunate in all of them.
Once again, in Joshua Lederberg, the University is fortunate to
have found a leader for the future who is qualified to match the
expectations created by this institution's experience with those who
have preceded him.
A scientist with a deep concern for improving public understanding
of science and its role in society, he comes to us from Stanford
University's School of Medicine, where he was chairman of the
Department of Medical Genetics and Joseph D. Grant Professor of
Genetics. A man of far-ranging interests, he has been active on a
variety of advisory committees and boards dealing with an equal
breadth of problems, including those of mental health and retardation
and environmental health. Winner of a Nobel Prize in 1958 at the age
of 33, Dr. Lederberg is an exceptionally gifted scientist of international
stature, one of that band of pioneers who has laid the foundations of
modern genetics, a field that is furnishing new techniques and valuable
insights for the biomedical research so central to the work of our
laboratories.

Presidential Address
JOSHUA LEDERBERG
President, The Rockefeller University

First of all, my welcome to you to this exhilarating occasion, and my
particular thanks to those of you who have come a long way from all
parts of the world. I am also especially pleased to see those of you who
have traversed 68th Street or York Avenue in the mood of fellowship
and cooperation that should increasingly bind our respective institu
tions.
Why would so many people go to such trouble for an event of this
kind? Anyone who has ever had to arrange for more than a dozen
people will respect the fuss and labor that it must entail. From my
own perspective, a ceremonial like this mainly gives pause to a new
incumbent, and to a venerable institution, for a process of self-exam
ination from which both may profit.
I am reminded of James B. Conant's admonition describing the
beginning of his long service as president of Harvard University, after
having returned there from a distinguished career as a laboratory
organic chemist.How grateful he was, he wrote in his autobiography,
that he was inadvertently thwarted in his plan to publish his initial
thoughts on entering: " ...that would have hung around my neck
during the next 20 years like the albatross of the ancient mariner."
But I am going to disregard his implicit advice, as indeed I have
tried hard to exhibit other disqualifications for an administrative role,
by trying to continue to behave as a laboratory scientist. In the latter
role, it is important to bring speculative ideas to the surface, where
others, as well as myself, can have a better opportunity to criticize,
sometimes even to discard, them. Furthermore, the scientist should be
quite fearless about appearing to be naive, ignorant, or even foolish
too often if you think you know the answer, you don't understand the
problem! My remarks are, then, in no respect settled truths, but reflect

initial quandaries and dilemmas in my trying to understand the larger
aspects of new responsibilities.
The fact is that none of our institutions can evade the most critical
examination, in the present climate of skepticism and inquiry about
our entire social fabric. If we do not examine and sometimes reform
ourselves, others will do so with even less information and insight. This
is then an apt moment to ask, as we should be prepared to ask at any
moment, "Just what would be lost if we disappeared from the face of
the earth?"
Perhaps there is even some special advantage in an incumbent's
tackling these issues before he is indeed encumbered by his day-to-day
obligations, and before he is embraced by the traditions and setting of
an institution so manifestly captivating as to prejudice that essential
self-examination. In fact, before proceeding more broadly, there are
two local elements of our setting worthy of comment.
First, this is the season of the equinox, with its unpredictable
alternations of climate and mood. In the ancient traditions of my co
religionists, the community built the harvest tabernacle as a symbol of
the indispensibility and frailty of our human constructions, of reliance
on a benign Providence for the recurrence of the nourishing rains, and
as a shelter against the torrential winds. In pursuing our academic
plans, we must still rely both on optimistic faith in ourselves and on
the support of a larger community.
In the crass terms of modern industrial society, a one-percent
fluctuation in the rate of inflation is the margin between fiscal stability
and disciplined growth on the one hand, and an inexorable slide into
insolvency on the other. We may congratulate ourselves in being far
closer to equilibrium today than are most other private academic
institutions. The most onerous and demoralizing adjustments-the
painful task of my predecessor Dr. Fred Seitz-are already behind us.
With hard work and just moc.lerate good luck, we have a planning
framework for vigorous survival. But it would take an egregious hubris
to ignore the possibility of still other unforeseeable storms; and we
must remind ourselves unremittingly how vulnerable we are to the
smallest fluctuation in public understanding of the integrity and
necessity of our mission. The task we face is both a material one of
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matching our plans and operations to a realistic model of the resources
available, and the spiritual one of sustaining our own confidence in
the importance of our work, and of communicating and shaping it to
the best interests of the human purposes we ultimately serve.
Another element in the setting for my remarks is the 75th Anniver
sary celebration of The Rockefeller University, held just two years
ago. Much of what I would want to say myself was already captured
by the statements of others at that time. Those accounts of the
transition from The Rockefeller Institute of Medical Research to The
Rockefeller University depict what attracted me to this place: not to
invoke radical changes, but to conserve the most vital traditions of
biomedical research to be found anywhere today.
It has become almost tedious to use this indicator, but of course we
do take some pride that still another of our research alumni, Dr.
Daniel Nathans, was honored with the Nobel Prize, announced just
last week. Dr. Nathans graduated from his clinical residency into
laboratory research here under the tutelage of Professor Fritz Lipmann
from 1959 to 1962, and I am sure that we all join in collegial
congratulations to him. We cannot be doing everything wrong with a
consistent record of recognition represented by the placement of
Rockefeller University graduates in leadership roles in medical re
search and education throughout the country.
The fundamental agenda of The Rockefeller University is indeed
basic biomedical research of substantial breadth in the tradition of
the Institute. The biomedical laboratory is the central focus of medical
research today: but it must have a still broader perspective-that of
the biochemical laboratory. We are fortunate in a faculty of world
recognized excellence in the behavioral sciences, as well as in experi
mental biology and pathology. And we can be informed by the still
different insights of physics and mathematics.
Now, scientific research is one of the most enthralling games that
can occupy the human mind, and those of us who can dedicate our
lifework to it are privileged indeed. But the private excitement of the
chase for new discovery should not obscure the enormous public stakes
of the enterprise-stakes that are trivialized by the attribution of mere
curiosity or by the better-selling Frankenstein images of the pop media.
Presidential Address
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What we learn today about the structure of DNA and of cells, and
how these are knit together in a functioning organism, is indispensible
tomorrow for what is indeed a war against pain, disease, and death.
There is no fundamental reason why we cannot learn to prevent all of
the major destroyers of long and happy lives that loom over the world
today: heart disease, cancer, mental illness, parasitic afflictions, birth
defects, even untimely aging. These tragic events are not inexorable
laws of matter and energy-they are side-effects of a natural evolu
tionary process that is both incomplete in its own script and indifferent
to the anguish of the human consciousness as we face our own
mortality.
Advances against these threats will not come cheaply, and the main
ones will, as the history of science has shown again and again, come
from the most unexpected and unprogrammed sources. The careers of
thousands of investigators are committed to them, and they, in turn,
require a level of material support that must be justified in competition
with many short-run social needs. They need moral support as well.
The ground rules for the ethical involvement of human subjects in
medical research are under constant scrutiny and revision, and evoke
an ever more cumbersome bureaucracy of supervision. Above all, the
lay citizen needs adequate information to be able to confront his own
soul about the choices ahead-whether to be a passive victim of
natural disease and disability, or to seize the chance to use new
knowledge for a rational frame of healthy life. There has been much,
sometimes hysterical, concern about the risks of medical research and
the need for public involvement. In my view, the most strident shocks
to familiar ways will come from the very success of our basic programs
of health research. No one will cast a vote against "living"; but we
have certainly not begun to face up to the social problems inherent in
biological solutions for the prolongation of life, even those that have
already been achieved in this century.
The primary responsibility that I avow in my new office is to help
sustain the traditions of excellence in science for which The Rockefeller
Institute and University has been justly famous for many decades.
The creative intellect of its carefully selected and gifted individual
members is the bedrock of accomplishment of any institution, and
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they must be furnished an enyironment and resources with which to
exercise their gifts. The substantial scope, but simple structure and
coherent goals, of this University offer a unique and attractive chal
lenge to scientific leadership. Beyond the list of our sixty independent
laboratories is an overarching opportunity to bring different specialties
of knowledge and styles of critical thinking together, both to enhance
scientific excellence and to confront all of these with the practical
challenges of human disease. The remarkable aspects of The Rocke
feller University: its appropriate size, traditions, setting, and range of
studies on one campus-encompassing molecular biology, the behav
ioral sciences, and the clinic-all offer unparalleled opportunities for
intellectual adventure and human service.
This conception of collegial effort is deeply embedded in the moti
vations both of our original founder and of the many individuals,
corporations, and foundations that have continued to support the
programs of The Rockefeller University. At its inception, the federal
support of biomedical research, mediated primarily through the Na
tional Institutes of Health, was implemented according to similar
ideals. Such support is absolutely indispensable and government grants
now account for half the annual operating budget of this University.
It is predictable but lamentable that this level of federal involvement
brings along an egregious degree of centralized management. Most of
this funding is directed to the "purchase" of specified research results,
packaged in projects, as if major discovery could be marketed accord
ing to such specifications. The project grant system, as admirably as
it has supported major innovations and discoveries in the past, is now
administered in ways that threaten to disintegrate institutions, to
discourage the confluence of creative ideas, and to impede opportun
istic collaborations of basic science and important clinical applications.
One of the most important functions of a private endowment is a
countercurrent to the services-rendered concept of the support of
research. In its place we return to the concept of venture capital
toward the identification of creative individuals and of collegial
frameworks better able to achieve the same social ends.
The need for collegiality and the attenuation of internal obstacles
to its realization also extend to the relationship between institutions.
Presidential Address
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Happily situated at the center of an extraordinary complex of
medical institutions-being literally now in the shadow of New York
and Memorial Hospitals, and immediate neighbors to Cornell Uni
versity Medical College and the Memorial Sloan-Kettering Cancer
Center-we have a remarkable opportunity to match our own intel
lectual style and skills, and dedication to the most basic science, with
the diverse problems and resources of our neighbors. They are deeply
preoccupied with medical education and the care of patients on a
large scale. These are social values of undeniable worth, but distinct
from what we can offer in tracing the underlying causes of disease. I
believe we have a particular obligation to focus on preventive health
applications: but I fear it will be quite a while before the hospitals are
no longer needed. We must work together to meet our categorical
social responsibilities, and I am delighted that even in the few weeks
of my tenure a number of measures for realistic partnership have been
started with the equally enthusiastic concurrence of our neighbors.
In closing, may I recall that I was educated in New York, having
had the privilege of access to Stuyvesant High School and to Columbia
University and Medical School, to the City's public library system
and many other institutions that foster intellectual development.
Having been away for many years and now returned, I feel especially
keenly how rich are these networks of sources. We are really all non
matriculated students in a metropolitan super-university. I will cer
tainly be doing all I can to enjoy this fare for myself and my colleagues,
and to seek ways in which our own specialized institution can most
efficiently cooperate with others truly "pro bono humani generis," for the
benefit of mankind. I am indeed grateful to the Board of Trustees, to
my colleagues, and to the community of our supporters and well
wishers for having created such an opportunity.
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BIOGRAPHIES
DR. THEODORE COOPER is dean of the Cornell University Medical College,
Provost of Medical Affairs, and Professor of Surgery and Pharmacology. His contri
butions as surgeon and educator have been enhanced by his development and
implementation of health policy at the highest governmental levels. Prior to his
appointment at Cornell, Dr. Cooper was Assistant Secretary for Health, U.S. Depart
ment of Health, Education and Welfare. Past government service also includes a six
year tenure as Director of the National Heart and Lung Institute of the National
Institutes of Health. He is a member of the governing boards of many health-related
foundations and organizations; in addition, he is active on the editorial boards of six
medical journals.
DR. GERALD M. EDELMAN, an authority on immunology and protein chemistry,
received a Nobel Prize in 1972 for his analysis of the amino acid sequence and internal
subunit structure of gamma globulin, the body's primary defense against foreign
substances and disease. He has been associated with The Rockefeller University since
1957, when he arrived as a graduate fellow. He received his Ph.D. and a faculty
appointment in 1960, and became full professor in 1966. In recognition of past
achievements and projected investigations relating to the formation of antibodies-a
research focus that may increase understanding of the treatment and prevention of
cancer-Dr. Edelman was appointed a Vincent Astor Professor in 1974.
DR. JOSHUA LEDERBERG, who became president of The Rockefeller University
on July 1, 1978, is a distinguished geneticist who was born in Montclair, New Jersey,
in 1925, attended Stuyvesant High School in New York, and received his B.A. degree
from Columbia College in 1944. After two years at Columbia University's College of
Physicians and Surgeons, he took a leave of absence to do research with the late
Edward L. Tatum at Yale University. He never returned to formal medical studies.
At first with Tatum, and later with other co-workers, Lederberg pioneered in bacterial
genetics research.
While at Yale, where he received his Ph.D. in 1947, he discovered the mechanism
of genetic recombination in bacteria, demonstrating for the first time that a form of
sexual reproduction occurs in these microorganisms. Eleven years later, at the age of
33, he was named a co-recipient of the Nobel Prize in Physiology or Medicine for this
work and subsequent research on bacterial genetics. The other recipients of the prize
that year were Dr. Tatum (who later joined The Rockefeller University faculty) and
Dr. George Beadle for their discovery at Stanford in the 1940s that genes act by
regulating specific chemical processes.
From 1947 to 1959, Dr. Lederberg was professor of genetics at the University of
Wisconsin and served two years ( 195 7-59) as chairman of a new Department of
Medical Genetics. In 1959, he joined the faculty of Stanford's School of Medicine,

where he served as chairman of the Department of Genetics and also held the titles of
professor of biology and professor of computer science. For four years, beginning in
1974, he was principal investigator and chairman of the executive committee of the
Stanford University Medical Experimental Computer-Artificial Intelligence in Med
icine project and continues as chairman of the executive committee.
A member of the National Academy of Sciences and a charter member of its
Institute of Medicine, Dr. Lederberg has been active on government advisory com
mittees and boards dealing with problems of mental health and retardation. He also
was a member of the Advisory Committee for Medical Research of the World Health
Organization, and is on the board of trustees of the Natural Resources Defense
Council, which is concerned with environmental health.
Dr. Lederberg played an active role in the Mariner and Viking missions to Mars,
sponsored by the National Aeronautics and Space Administration. He was a consul
tant to the Arms Control and Disarmament Agency during the successful negotiation
of the treaty on biological weapons disarmament. He is a director of the Center for
Advanced Study in the Behavioral Sciences, Stanford, and of the Institute of Scientific
Information in Philadelphia. He is also chairman of the board of Annual Reviews of
Palo Alto, California, a cooperative, nonprofit scientific publisher.
Dr. Lederberg has been awarded honorary Doctor of Science degrees by Yale,
Columbia, University of Wisconsin, and The Mount Sinai and Albert Einstein colleges
of medicine, and an honorary M.D. by the University of Turin, Italy. He has also
been elected a foreign member of the Royal Society.
His interest in improving communications among scientists, the general public,
and government policy makers has led Dr. Lederberg to write extensively for lay
audiences, including a series of columns, distributed by the Washington Post Syndi
cate, on the social impact of scientific programs.
DR. LEWIS THOMAS is President and Chief Executive Officer of Memorial Sloan
Kettering Cancer Center. He also holds appointments as professor of pathology and
medicine at Cornell University Medical College, and attending physician at Memorial
Hospital. Dr. Thomas has been a specialist in pediatrics as well as in pathology; a
hospital administrator; an instructor in many medical schools, including those at Yale
and New York University, where he was also dean; a government consultant; and a
popular author. Dr. Thomas's collection of essays entitled The Lives of a Cell won a
National Book Award in 1974. Recognition of his accomplishments is reflected in his
election to the boards of many eminent foundations and institutions, including The
Rockefeller University.
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